Company profile: Noveome Biotherapeutics
1.1 - Company Overview
Company description
- Provider of regenerative repair therapies for inflamed or damaged tissues via ST266, a multi-targeted secretome of biologically active proteins for neuroprotection, inflammation modulation, cell recovery, and healing in ophthalmology, neurology, and dermatology; explored in PEDs, optic neuritis, glaucoma (Phase I), NEC, and COVID-19/sepsis cytokine storm.
Products and services
- ST266: A multi-targeted secretome containing hundreds of biologically active proteins and factors for neuroprotection, modulation of inflammation, cell recovery, and healing across ophthalmology, neurology, and dermatology
- Glaucoma: Phase I clinical-stage evaluation where ST266 demonstrates preclinical neuroprotective effects to protect optic nerve cells from damage caused by elevated intraocular pressure
- Persistent Corneal Epithelial Defects (PEDs): Clinical-trial–evaluated use of ST266 to reduce corneal inflammation and enhance re-epithelialization in slow-healing wounds often linked to diabetes or immune deficiencies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Noveome Biotherapeutics
Kynos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule KMO inhibitor therapeutics for inflammation, immunity, and metabolism. Offers KNS366, a Phase I KMO inhibitor designed to reduce elevated 3-HK to prevent tissue damage and immune dysregulation during inflammation, and a portfolio targeting acute and chronic inflammatory disorders, including acute kidney injury and acute pancreatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kynos Therapeutics company profile →
Avalo Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies developing monoclonal antibodies and a fusion protein for inflammatory diseases, including AVTX-009 (anti-IL-1β), quisovalimab (anti-LIGHT), AVTX-008 (BTLA agonist fusion protein), and AVTX-002 (fully human anti-LIGHT, in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalo Therapeutics company profile →
VG Life Sciences
HQ: United States
Website
- Description: Provider of drug therapy discovery and development for cancers, infectious diseases, inflammatory diseases, and autoimmune disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VG Life Sciences company profile →
Amunix
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, discovering, designing, and developing novel biologics, protein, and peptide therapeutics, with a focus on prodrugs that enable potent immune-activating biotherapeutics for patients with solid tumor cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amunix company profile →
Eleusis
HQ: United Kingdom
Website
- Description: Provider of clinical-stage psychedelic-based therapeutics and care delivery solutions, including ELE-Psilo, an investigational IV psilocin candidate for major depressive disorder; a platform for screening, treatment, monitoring, and continuing care to enhance safety, personalization, and accessibility; clinic operations via Andala providing access to psychiatric drug therapies; and discovery programs for anti-inflammatory, neuroprotective, and other psychiatric and non-psychiatric medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleusis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Noveome Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Noveome Biotherapeutics
2.2 - Growth funds investing in similar companies to Noveome Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Noveome Biotherapeutics
4.2 - Public trading comparable groups for Noveome Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →